Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

exelixis inc. - EXEL

EXEL

Close Chg Chg %
35.61 0.97 2.72%

Open Market

36.58

+0.97 (2.72%)

Volume: 1.03M

Last Updated:

Nov 25, 2024, 3:19 PM EDT

Trade Now

Company Overview: exelixis inc. - EXEL

EXEL Key Data

Open

$35.80

 Day Range

35.80 - 36.62

52 Week Range

19.21 - 36.60

 Market Cap

$10.17B

Shares Outstanding

285.58M

 Public Float

278.44M

Beta

0.51

 Rev. Per Employee

N/A

P/E Ratio

22.69

 EPS

$1.60

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.45M

  

EXEL Performance

1 Week
 
 3.37%
 
1 Month
 
 27.77%
 
3 Months
 
 37.60%
 
1 Year
 
 64.25%
 
5 Years
 
 118.73%
 

EXEL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 23
Full Ratings ➔

About exelixis inc. - EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

EXEL At a Glance

Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda, California 94502
Phone 1-650-837-7000 Revenue 1.83B
Industry Pharmaceuticals: Major Net Income 207.77M
Sector Health Technology 2023 Sales Growth 13.603%
Fiscal Year-end 12 / 2024 Employees 1,310
View SEC Filings

EXEL Valuation

P/E Current 22.693
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 37.119
Price to Sales Ratio 4.214
Price to Book Ratio 3.209
Price to Cash Flow Ratio 23.136
Enterprise Value to EBITDA 35.26
Enterprise Value to Sales 3.788
Total Debt to Enterprise Value 0.031

EXEL Efficiency

Revenue/Employee 1,397,105.344
Income Per Employee 158,599.237
Receivables Turnover 7.306
Total Asset Turnover 0.603

EXEL Liquidity

Current Ratio 3.343
Quick Ratio 3.299
Cash Ratio 2.524

EXEL Profitability

Gross Margin 96.036
Operating Margin 9.337
Pretax Margin 14.071
Net Margin 11.352
Return on Assets 6.848
Return on Equity 8.744
Return on Total Capital 8.379
Return on Invested Capital 8.096

EXEL Capital Structure

Total Debt to Total Equity 9.526
Total Debt to Total Capital 8.697
Total Debt to Total Assets 7.197
Long-Term Debt to Equity 8.39
Long-Term Debt to Total Capital 7.66
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Exelixis Inc. - EXEL

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
987.54M 1.43B 1.61B 1.83B
Sales Growth
+2.04% +45.31% +12.27% +13.60%
Cost of Goods Sold (COGS) incl D&A
36.27M 52.87M 57.91M 72.55M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
13.97M 13.63M 20.88M 25.72M
Depreciation
13.97M 13.63M 20.88M 25.72M
Amortization of Intangibles
- - - -
-
COGS Growth
+9.59% +45.77% +9.52% +25.28%
Gross Income
951.27M 1.38B 1.55B 1.76B
Gross Income Growth
+1.77% +45.29% +12.38% +13.17%
Gross Profit Margin
+96.33% +96.32% +96.41% +96.04%
2020 2021 2022 2023 5-year trend
SG&A Expense
841.21M 1.10B 1.35B 1.59B
Research & Development
547.85M 693.72M 891.81M 1.04B
Other SG&A
293.36M 401.71M 459.86M 542.71M
SGA Growth
+48.83% +30.22% +23.39% +17.39%
Other Operating Expense
- - - -
-
Unusual Expense
- - (800.00K) (1.20M)
-
EBIT after Unusual Expense
110.06M 287.47M 202.68M 170.88M
Non Operating Income/Expense
20.78M 6.69M 31.67M 86.64M
Non-Operating Interest Income
19.86M 7.67M 33.06M 86.54M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
130.84M 294.15M 234.35M 257.52M
Pretax Income Growth
-67.14% +124.82% -20.33% +9.89%
Pretax Margin
+13.25% +20.50% +14.55% +14.07%
Income Tax
19.06M 63.09M 52.07M 49.76M
Income Tax - Current - Domestic
- 3.79M 112.43M 182.97M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- 15.27M (60.36M) (133.21M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
111.78M 231.06M 182.28M 207.76M
Minority Interest Expense
- - - -
-
Net Income
111.78M 231.06M 182.28M 207.76M
Net Income Growth
-65.18% +106.71% -21.11% +13.98%
Net Margin Growth
+11.32% +16.10% +11.31% +11.35%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
111.78M 231.06M 182.28M 207.76M
Preferred Dividends
- - - -
-
Net Income Available to Common
111.78M 231.06M 182.28M 207.76M
EPS (Basic)
0.3626 0.7338 0.5669 0.653
EPS (Basic) Growth
-65.82% +102.37% -22.74% +15.19%
Basic Shares Outstanding
308.27M 314.88M 321.53M 318.15M
EPS (Diluted)
0.3515 0.7168 0.5616 0.6463
EPS (Diluted) Growth
-65.51% +103.93% -21.65% +15.08%
Diluted Shares Outstanding
318.00M 322.36M 324.56M 321.46M
EBITDA
124.03M 300.30M 222.36M 196.60M
EBITDA Growth
-67.41% +142.11% -25.95% -11.58%
EBITDA Margin
+12.56% +20.93% +13.80% +10.74%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 32.35
Number of Ratings 23 Current Quarters Estimate 0.383
FY Report Date 12 / 2024 Current Year's Estimate 1.656
Last Quarter’s Earnings 0.40 Median PE on CY Estimate N/A
Year Ago Earnings 0.65 Next Fiscal Year Estimate 1.64
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 5 16 17
Mean Estimate 0.38 0.34 1.66 1.64
High Estimates 0.52 0.44 1.89 2.20
Low Estimate 0.20 0.26 1.45 1.10
Coefficient of Variance 22.01 23.93 8.15 20.58

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 14
OVERWEIGHT 0 0 1
HOLD 7 7 5
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Exelixis Inc. - EXEL

Date Name Shares Transaction Value
Nov 8, 2024 Dana T. Aftab CSO/EVP Disc & Trans Research N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 8, 2024 Dana T. Aftab CSO/EVP Disc & Trans Research 498,945 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35 per share 17,463,075.00
Nov 8, 2024 Dana T. Aftab CSO/EVP Disc & Trans Research 595,931 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.8 per share 11,203,502.80
Oct 4, 2024 Patrick J. Haley EVP, Commercial 441,036 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.41 per share 10,765,688.76
Oct 4, 2024 Patrick J. Haley EVP, Commercial N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 4, 2024 Patrick J. Haley EVP, Commercial 344,925 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.5 per share 9,140,512.50
Oct 4, 2024 Michael M. Morrissey President and CEO; Director 1,444,384 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.41 per share 35,257,413.44
Oct 4, 2024 Michael M. Morrissey President and CEO; Director 980,682 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.3 per share 25,791,936.60
Oct 4, 2024 Michael M. Morrissey President and CEO; Director 964,384 Bona fide gift 0.00
Oct 4, 2024 Michael M. Morrissey President and CEO; Director 1,453,212 Bona fide gift 0.00
Oct 4, 2024 Michael M. Morrissey President and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Jack L. Wyszomierski Director 349,499 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22 per share 7,688,978.00
Jun 5, 2024 Mary C. Beckerle Director 34,262 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Julie Anne Smith Director 20,030 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Julie Anne Smith Director 15,460 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Stelios Papadopoulos Director 1,279,416 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Sue Gail Eckhardt Director 34,262 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Robert L. Oliver Director 37,014 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 George A. Poste Director 232,745 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Maria C. Freire Director 99,257 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Exelixis Inc. in the News